MCID: INC003
MIFTS: 35

Inclusion Conjunctivitis

Categories: Eye diseases, Infectious diseases, Rare diseases

Aliases & Classifications for Inclusion Conjunctivitis

MalaCards integrated aliases for Inclusion Conjunctivitis:

Name: Inclusion Conjunctivitis 12 75 53 15 17 72
Chlamydial Conjunctivitis 12 33
Inclusion Conjunctivitis of the Adult 72
Neonatal Chlamydial Conjunctivitis 72
Adult Inclusion Conjunctivitis 12
Conjunctivitis, Inclusion 44
Inclusion Blennorrhoea 12
Inclusion Blenorrhea 12
Paratrachoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:13800
ICD9CM 35 077.0
MeSH 44 D003235
SNOMED-CT 68 56009001
ICD10 33 A74.0
UMLS 72 C0009770 C0343723 C0392644

Summaries for Inclusion Conjunctivitis

Disease Ontology : 12 A commensal bacterial infectious disease that results in inflammation, located in conjunctiva of the eye, has material basis in Chlamydia trachomatis, which is transmitted by sexual contact. The infection has symptom swollen conjunctiva and eyelids and has symptom discharge of pus and mucus.

MalaCards based summary : Inclusion Conjunctivitis, also known as chlamydial conjunctivitis, is related to conjunctivitis and trachoma, and has symptoms including swollen conjunctiva and discharge of pus. An important gene associated with Inclusion Conjunctivitis is WDR13 (WD Repeat Domain 13). The drugs Ganciclovir and silver nitrate have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and t cells, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 75 Conjunctivitis, also known as pink eye, is inflammation of the outermost layer of the white part of the... more...

Related Diseases for Inclusion Conjunctivitis

Graphical network of the top 20 diseases related to Inclusion Conjunctivitis:



Diseases related to Inclusion Conjunctivitis

Symptoms & Phenotypes for Inclusion Conjunctivitis

Symptoms:

12
  • swollen conjunctiva
  • discharge of pus

GenomeRNAi Phenotypes related to Inclusion Conjunctivitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 CD40LG GPR132 WDR13
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 CD40LG GPR132 WDR13

Drugs & Therapeutics for Inclusion Conjunctivitis

Drugs for Inclusion Conjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 31)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ganciclovir Approved, Investigational Phase 3 82410-32-0 3454
2 silver nitrate Approved, Investigational Phase 3
3
Erythromycin Approved, Investigational, Vet_approved Phase 3 114-07-8 441411 12560
4
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
5
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
6
Povidone Approved Phase 3 9003-39-8
7
Iodine Approved, Investigational Phase 3 7553-56-2 807
8
Povidone-iodine Approved Phase 3 25655-41-8
9 Antiviral Agents Phase 3
10 Lubricant Eye Drops Phase 3
11 Ganciclovir triphosphate Phase 3
12 Nucleic Acid Synthesis Inhibitors Phase 3
13 Erythromycin Ethylsuccinate Phase 3
14 Erythromycin stearate Phase 3
15 Erythromycin Estolate Phase 3
16 Hormone Antagonists Phase 3
17 Antiemetics Phase 3
18 HIV Protease Inhibitors Phase 3
19 Hormones Phase 3
20
protease inhibitors Phase 3
21 Peripheral Nervous System Agents Phase 3
22 Anti-Inflammatory Agents Phase 3
23 glucocorticoids Phase 3
24 Antineoplastic Agents, Hormonal Phase 3
25 Autonomic Agents Phase 3
26 BB 1101 Phase 3
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
28 cadexomer iodine Phase 3
29 Anti-Infective Agents, Local Phase 3
30 Anti-Infective Agents Phase 3
31
Azithromycin Approved 83905-01-5 447043 55185

Interventional clinical trials:

(show all 14)
# Name Status NCT ID Phase Drugs
1 "Prospective, Interventional, Randomized, Double-masked With the Use of Ganciclovir Gel 0.3% for Treatment of Conjunctivitis Caused by Adenovirus." Unknown status NCT01600365 Phase 3 Ophthalmic gel (placebo);Ganciclovir
2 Clinical Trial of Eye Prophylaxis in the Newborn Completed NCT00000120 Phase 3 Erythromycin Ointment;Silver Nitrate Drops
3 A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to Placebo in the Treatment of Adenoviral Conjunctivitis Terminated NCT02998554 Phase 3 SHP640;Placebo
4 A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to PVP-Iodine and Placebo in the Treatment of Adenoviral Conjunctivitis Terminated NCT02998541 Phase 3 SHP640;PVP-I 0.6%
5 A Proof-of-Concept, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of FST-100 Ophthalmic Suspension in the Treatment of Acute Adenoviral Conjunctivitis Completed NCT01470664 Phase 2 FST-100;FST-100 (Component #1);FST-100 Vehicle
6 A Multicenter, Randomized Study of the Efficacy and Safety of NVC-422 Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis Completed NCT01532336 Phase 2 NVC-422 Solution, 0.3%;NVC-422 Vehicle Solution
7 A Phase 2, Multi-centeR, Randomized, DoUBle-Masked, Placebo-Controlled StudY to Evaluate the Clinical Safety and Efficacy of OKG-0301 in the Treatment of Acute Adenoviral Conjunctivitis Recruiting NCT03856645 Phase 2 OKG-0301
8 A Double-Masked, Placebo-Controlled, Randomized, Phase II Clinical Trial To Assess The Efficacy Of IVIEW-1201 In The Treatment Of Acute Adenoviral Conjunctivitis Not yet recruiting NCT03749317 Phase 2 IVIEW-1201;Placebo
9 FST-100 Ophthalmic Suspension in Acute Adenoviral Conjunctivitis Terminated NCT00941486 Phase 2 FST-100 (0.1% dexamethasone) Ophthalmic Suspension;Placebo
10 An Evaluation of the Efficacy and Safety of AL-46383A Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis Terminated NCT00901693 Phase 2 AL-46383A Ophthalmic Solution;AL-46383A Ophthalmic Solution Vehicle
11 Evaluation of the Efficacy and Safety of Iota-Carrageenan Eye Drops (NCX-4240) Versus Placebo in Patients With Adenoviral Conjunctivis Withdrawn NCT03009799 Phase 2 Iota-Carrageenan;Carmellose
12 The Effect of Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis Completed NCT01178762 Azithromycin
13 A Prospective Blinded Multi-center Clinical Trial to Evaluate the Efficacy of the Recently FDA Approved RPS Adeno Detector for Detecting Adenoviral Conjunctivitis Completed NCT00266734
14 Reducing Adenoviral Patient Infected Days Recruiting NCT02472223 Betadine 5%;Artificial Tears

Search NIH Clinical Center for Inclusion Conjunctivitis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Acetyl sulfisoxazole
Demeclocycline
Erythromycin
Minocycline
Sulfadiazine
Tetracycline

Cochrane evidence based reviews: conjunctivitis, inclusion

Genetic Tests for Inclusion Conjunctivitis

Anatomical Context for Inclusion Conjunctivitis

MalaCards organs/tissues related to Inclusion Conjunctivitis:

41
Eye, Testes, T Cells, Colon, Neutrophil, Skeletal Muscle

The Foundational Model of Anatomy Ontology organs/tissues related to Inclusion Conjunctivitis:

19
Conjunctiva Of The Eye

Publications for Inclusion Conjunctivitis

Articles related to Inclusion Conjunctivitis:

(show top 50) (show all 408)
# Title Authors PMID Year
1
Chlamydia trachomatis presenting as preseptal cellulitis in a 3-year-old girl. 38
31112775 2019
2
Symptoms, Signs and Long-term Prognosis of Vertically Transmitted Chlamydia trachomatis Infections. 38
29389825 2018
3
Treatment of Neonatal Chlamydial Conjunctivitis: A Systematic Review and Meta-analysis. 38
30007329 2018
4
Effects of iota-carrageenan on ocular Chlamydia trachomatis infection in vitro and in vivo. 38
30147240 2018
5
Interventions for treating genital Chlamydia trachomatis infection in pregnancy. 38
28937705 2017
6
Neonatal Bacterial Conjunctivitis in Korea in the 21st Century. 38
28002109 2017
7
Chlamydial conjunctivitis in newborns: Case report and screening opportunities. 38
28177584 2017
8
Chlamydial eye infections: Current perspectives. 38
28345563 2017
9
[Persistent, therapy-resistant conjunctivitis: consider infection with Chlamydia trachomatis]. 38
28443807 2017
10
The presence of Chlamydia phage PhiCPG1 capsid protein VP1 genes and antibodies in patients infected with Chlamydia trachomatis. 38
27213552 2016
11
Study of the prevalence and association of ocular chlamydial conjunctivitis in women with genital infection by Chlamydia trachomatis, Mycoplasma genitalium and Candida albicans attending outpatient clinic. 38
27588273 2016
12
Chlamydial conjunctivitis: prevalence and serovar distribution of Chlamydia trachomatis in adults. 38
26297635 2015
13
Preventing ophthalmia neonatorum. 38
26236350 2015
14
Conjunctival infection with Chlamydia trachomatis in sexual partners of patients with adult inclusion conjunctivitis. 38
24643518 2015
15
Preventing ophthalmia neonatorum. 38
25838784 2015
16
Chlamydia trachomatis conjunctivitis in a male teenager: a case report. 38
24955802 2014
17
Evaluation of single-dose azithromycin versus standard azithromycin/doxycycline treatment and clinical assessment of regression course in patients with adult inclusion conjunctivitis. 38
24047438 2013
18
Evaluation of direct immunofluorescence assay and cytological examination in comparison to polymerase chain reaction of conjunctival swabs in patients with adult inclusion conjunctivitis. 38
23627371 2013
19
Multiplex PCR testing requires a robust multi-disciplinary strategy to effectively manage identified cases of chlamydial conjunctivitis. 38
23728751 2013
20
[Purulent keratoconjunctivitis due to Neisseria gonorrhoeae and Chlamydia trachomatis coinfection]. 38
23692878 2013
21
[Investigation of Chlamydia trachomatis with Cell Culture, DFA and PCR Methods in the Genital Swab Samples of Symptomatic Patients]. 38
23390905 2013
22
[Prevalence of Chlamydia trachomatis in adults with chronic conjunctivitis in Nisava district]. 38
22650098 2012
23
The use of polymerase chain reaction assay versus cell culture in detecting neonatal chlamydial conjunctivitis. 38
22369307 2012
24
Effect of inflammatory response on in vivo competition between two chlamydial variants in the guinea pig model of inclusion conjunctivitis. 38
22144478 2012
25
Features and serotypes of chlamydial conjunctivitis. 38
22230301 2012
26
Essential role for neutrophils in pathogenesis and adaptive immunity in Chlamydia caviae ocular infections. 38
21402767 2011
27
Effect of oral azithromycin in the treatment of chlamydial conjunctivitis. 38
19893589 2010
28
Bilateral conjunctival MALT lymphoma mimicking chronic conjunctivitis. 38
20523096 2010
29
Midterm results of cultivated autologous and allogeneic limbal epithelial transplantation in limbal stem cell deficiency. 38
20502027 2010
30
Chlamydia trachomatis causing neonatal conjunctivitis in a tertiary care center. 38
20061763 2010
31
Recent trends in chlamydial and gonococcal conjunctivitis among neonates and adults in an Irish hospital. 38
18093859 2008
32
The use of polymerase chain reaction assay versus conventional methods in detecting neonatal chlamydial conjunctivitis. 38
18705621 2008
33
Bacterial conjunctivitis: a review for internists. 38
18646586 2008
34
Randomised equivalency trial comparing 2.5% povidone-iodine eye drops and ophthalmic chloramphenicol for preventing neonatal conjunctivitis in a trachoma endemic area in southern Mexico. 38
17947266 2007
35
Chlamydial conjunctivitis presenting as pre septal cellulitis. 38
17359543 2007
36
Incidence of neonatal chlamydial conjunctivitis and its association with nasopharyngeal colonisation in a Hong Kong hospital, assessed by polymerase chain reaction. 38
17277388 2007
37
Can chlamydial conjunctivitis result from direct ejaculation into the eye? 38
16942659 2006
38
Otitis media in adults with chlamydial conjunctivitis. 38
16731671 2006
39
Neonatal chlamydial conjunctivitis. 38
16760561 2006
40
Chlamydiales in guinea-pigs and their zoonotic potential. 38
16629952 2006
41
Neonatal haemorrhagic conjunctivitis: a specific sign of chlamydial infection. 38
16495586 2006
42
Chlamydia trachomatis infections in neonates and young children. 38
16210104 2005
43
The Relationship between chlamydia trachomatis and chlamydia pneumoniae as the cause of neonatal conjunctivitis (ophthalmia neonatorum). 38
16088243 2005
44
Conjunctival swab cytology from a guinea pig: it's elementary! 38
15902672 2005
45
Feline chlamydiosis. 38
15948428 2005
46
Cell death, BAX activation, and HMGB1 release during infection with Chlamydia. 38
15488733 2004
47
Chronic penile oedema secondary to chronic masturbation. 38
15228737 2004
48
Current problems of perinatal Chlamydia trachomatis infections. 38
14962349 2004
49
Combination of adult inclusion conjunctivitis and mucosa-associated lymphoid tissue (MALT) lymphoma in a young adult. 38
14701961 2004
50
Characterization of chlamydial genital infection resulting from sexual transmission from male to female guinea pigs and determination of infectious dose. 38
14573630 2003

Variations for Inclusion Conjunctivitis

Expression for Inclusion Conjunctivitis

Search GEO for disease gene expression data for Inclusion Conjunctivitis.

Pathways for Inclusion Conjunctivitis

GO Terms for Inclusion Conjunctivitis

Sources for Inclusion Conjunctivitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....